本研究以X公司為例，探討X公司的質譜儀設備在中國醫療檢測市場的策略選擇。從跨國企業在中國市場面臨的挑戰，看到中國醫療檢測市場的機會，根據外部政治經濟的變化，中國政府支持產業的本土製造，加上X公司內部其他產品線競爭激烈的困境急需找到下一個藍海市場，而醫療檢測市場又需要價格低與檢測項目多的產品，因此，針對X公司的質譜儀設備與檢測試劑盒的本地化生產的兩個維度，依照維持現狀、自行製造與外包生產，交叉組合做出八個策略。
接者，依據產品與機會優缺點的分析，加上交易成本與產品上市時間的分析，得出X公司在中國的質譜儀設備與檢測試劑盒的本地化生產皆以外包生產的方式，最符合X公司在中國醫療檢測市場的最佳策略選擇。

關鍵字:交易成本、策略選擇、醫療檢測市場、質譜儀

This study takes Company X as an example to discuss the strategic choices of Company X's mass spectrometer equipment in China's medical testing market. From the challenges faced by multinational companies in the Chinese market, to see the opportunities in the Chinese medical testing market, according to external political and economic changes, the Chinese government supports the local manufacturing of the industry, coupled with the dilemma of fierce competition in other product lines within X Company, it is urgent to find the next one The blue ocean market, and the medical testing market requires products with low prices and many testing items. Therefore, for the two dimensions of the localized production of X Company's mass spectrometer equipment and testing kits, according to maintaining the status quo, self-manufacturing and outsourcing production, Cross combinations to make eight strategies.
According to the analysis of the advantages and disadvantages of products and opportunities, plus the analysis of transaction costs and product launch time, it is concluded that the localized production of mass spectrometer equipment and detection kits of X Company in China is all outsourced, which is the most suitable method. Company X's best strategic choice in China's medical testing market.

Keywords: transaction cost, strategy choice, medical testing market, mass spectrometer

參考文獻
一、中文文獻
工業和資訊化部 (2017) 工業和資訊化部關於印發《產業關鍵共性技術發展指南（2017年）》的通知，https://www.miit.gov.cn/zwgk/zcwj/wjfb/zh/art/2020/art_ea0c261a60564111a11ecabecf60030a.html，搜尋時間: 2022年11月2日。
王敦仁(2020)，質譜儀成代謝體學檢驗利器，使精準醫療更完善—專訪馬偕醫院王敦仁資深醫檢師， 基因線上 https://geneonline.news/interview-with-tuan-jen-wang/，搜尋時間: 2022年11月2日。
中商產業研究院 (2021) 2020年中國質譜儀進出口貿易及全球市場競爭格局數據分析，https://twgreatdaily.com/511109765_350221-sh.html，搜尋時間: 2022年11月2日。
江琦，2017，臨床質譜檢測: 診斷領域中的另一個基因測序，中泰證券研究報告 ，http://pdf.dfcfw.com/pdf/H3_AP201712131065767179_1.pdf ，搜尋時間: 2022年11月2日。
中文維基百科，交易成本，https://zh.wikipedia.org/zh-hant/%E4%BA%A4%E6%98%93%E6%88%90%E6%9C%AC ，搜尋時間: 2022年11月2日。
中國政府網(2015) 李克強在2015夏季達沃斯論壇開幕式上的致辭實錄，http://big5.www.gov.cn/gate/big5/www.gov.cn/guowuyuan/2015-09/10/content_2928456.htm，搜尋時間: 2022年11月2日。
陳向明. (2002). 社会科學質的硏究 ，台北，台灣，五南圖書出版股份有限公司.
賴建成、蔡輔仁，2003，質譜術於臨床醫學之應用，科儀新知，第25卷第1期 : 18-32
羅政與劉卓(2022) 信達證券實驗分析儀器系列報告之質譜儀(二) :產業升級國產替代https://pdf.dfcfw.com/pdf/H3_AP202202071545429383_1.pdf?1644239926000.pdf，搜尋時間: 2022年11月2日。

二、西文文獻
Ackermann, B. L., Berna, M. J., Eckstein, J. A., Ott, L. W., & Chaudhary, A. K. (2008). Current applications of liquid chromatography/mass spectrometry in pharmaceutical discovery after a decade of innovation. Annu. Rev. Anal. Chem., 1, 357-396.
Baranoff, E., Curchod, B. F., Frey, J., Scopelliti, R., Kessler, F., Tavernelli, I., ... & Nazeeruddin, M. K. (2012). Acid-induced degradation of phosphorescent dopants for OLEDs and its application to the synthesis of tris-heteroleptic iridium (III) bis-cyclometalated complexes. Inorganic chemistry, 51(1), 215-224.
Bravo, A. A., Sheth, S. G., & Chopra, S. (2001). Liver biopsy. New England Journal of Medicine, 344(7), 495-500.
Bogdewic, S. P. (1992). Participant observation.
Coase, R. H. (1937). The nature of the firm. The nature of the firm, 18-33, 386-405.
Day, G. S. (1994). The capabilities of market-driven organizations. Journal of marketing, 58(4), 37-52.
Deshpandé, R., Farley, J. U., & Webster Jr, F. E. (1993). Corporate culture, customer orientation, and innovativeness in Japanese firms: a quadrad analysis. Journal of marketing, 57(1), 23-37.
Eisenhardt, K. M. (1989). Building theories from case study research. Academy of Management review, 14(4), 532-550.Ford, D., & Farmer, D. (1986). Make or buy—a key strategic issue. Long Range Planning, 19(5), 54-62.
Gowda, G. N., Zhang, S., Gu, H., Asiago, V., Shanaiah, N., & Raftery, D. (2008). Metabolomics-based methods for early disease diagnostics. Expert review of molecular diagnostics, 8(5), 617-633.
Gowda, G. A., & Djukovic, D. (2014). Overview of mass spectrometry-based metabolomics: opportunities and challenges. Mass Spectrometry in Metabolomics, 3-12.
Holmes, E., Nicholson, J. K., Nicholls, A. W., Lindon, J. C., Connor, S. C., Polley, S., & Connelly, J. (1998). The identification of novel biomarkers of renal toxicity using automatic data reduction techniques and PCA of proton NMR spectra of urine. Chemometrics and Intelligent Laboratory Systems, 44(1-2), 245-255.
Jennings, D. (1997). Strategic guidelines for outsourcing decisions. Strategic Change, 6(2), 85-96.
Jia, W., Xie, G., & Jia, W. (2018). Bile acid–microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nature reviews Gastroenterology & hepatology, 15(2), 111-128.
Kremic, T., Tukel, O. I., & Rom, W. O. (2006). Outsourcing decision support: a survey of benefits, risks, and decision factors. Supply Chain Management: An International Journal, 467, 482.
Kushnir, M. M., Rockwood, A. L., & Bergquist, J. (2010). Liquid chromatography–tandem mass spectrometry applications in endocrinology. Mass spectrometry reviews, 29(3), 480-502.
Lin, D. Y., Sheen, I. S., Chiu, C. T., Lin, S. M., Kuo, Y. C., & Liaw, Y. F. (1993). Ultrasonographic changes of early liver cirrhosis in chronic hepatitis B: a longitudinal study. Journal of clinical ultrasound, 21(5), 303-308.
Liu, Y., Hong, Z., Tan, G., Dong, X., Yang, G., Zhao, L. & Chai, Y. (2014). NMR and LC/MS‐based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis. International journal of cancer, 135(3), 658-668.
Luan, Z., Xie, C., Duan, L., Wang, Z., & Xiong, Y. (2009). Risk identification based on OEM supply chain. In 2009 International Conference on Management and Service Science (pp. 1-4). IEEE.
Lukas, B. A., & Ferrell, O. C. (2000). The effect of market orientation on product innovation. Journal of the Academy of Marketing Science, 28(2), 239-247.
Malik, A. K., Blasco, C., & Picó, Y. (2010). Liquid chromatography–mass spectrometry in food safety. Journal of Chromatography A, 1217(25), 4018-4040.
Matta, A., DeSouza, L. V., Shukla, N. K., Gupta, S. D., Ralhan, R., & Siu, K. M. (2008). Prognostic Significance of Head-and-Neck Cancer Biomarkers Previously Discovered and Identified Using iTRAQ-Labeling and Multidimensional Liquid Chromatography− Tandem Mass Spectrometry. Journal of proteome research, 7(5), 2078-2087.
McIvor, R. T., Humphreys, P. K., & McAleer, W. E. (1997). A strategic model for the formulation of an effective make or buy decision. Management Decision, 35(2), 169-178.
McIvor, R. T., & Humphreys, P. K. (2000). A case-based reasoning approach to the make or buy decision. Integrated Manufacturing Systems, 11(5), 295-310.
North, D. C., & North, D. C. (1992). Transaction costs, institutions, and economic performance (pp. 13-15). San Francisco, CA: ICS Press.
Platts, K. W., Probert, D. R., & Canez, L. (2002). Make vs. buy decisions: A process incorporating multi-attribute decision-making. International journal of production economics, 77(3), 247-257.
Quinn, J. B., & Hilmer, F. G. (1994). Strategic outsourcing. MIT Sloan Management Review, 35(4), 43.
Quinn, R. A., Nothias, L. F., Vining, O., Meehan, M., Esquenazi, E., & Dorrestein, P. C. (2017). Molecular networking as a drug discovery, drug metabolism, and precision medicine strategy. Trends in pharmacological sciences, 38(2), 143-154.
Slater, S. F., & Narver, J. C. (1996). Competitive strategy in the market-focused business. Journal of market-focused management, 1(2), 159-174.
Strategic Directions International, SDi (2021) 2021 Mass Spectrometry Market for Clinical Applications. SDi, part of Science and Medicine Group, Report 21-008
Trifonova, O. P., Maslov, D. L., Balashova, E. E., & Lokhov, P. G. (2021). Mass spectrometry-based metabolomics diagnostics–myth or reality?. Expert Review of Proteomics, 18(1), 7-12.
van den Ouweland, J. M., & Kema, I. P. (2012). The role of liquid chromatography–tandem mass spectrometry in the clinical laboratory. Journal of chromatography B, 883, 18-32.
Venkatesan, R. (1992). Strategic sourcing: To make or not to make. Harvard Business Review, 70(6), 98-107.
Whiting, M. J. (2009). Simultaneous measurement of urinary metanephrines and catecholamines by liquid chromatography with tandem mass spectrometric detection. Annals of Clinical Biochemistry, 46(2), 129-136.
Williamson, O. E. (1981). The economics of organization: The transaction cost approach. American journal of sociology, 87(3), 548-577.
Yin, R. K. (1994). Case study research: design and methods, applied social research methods series. Biography, Sage Publications, London.